Developer docs
API playgroundTry for free, no card

Search company profiles

Cullinan Therapeutics

Full company profile

uuid0000ela

Namestring
Cullinan Therapeutics
Legal namestring
Cullinan Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2016
Short descriptiontext

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing bispecific T cell engagers (CD19xCD3, BCMAxCD3, FLT3xCD3) and the partnered EGFR inhibitor zipalertinib for autoimmune diseases and oncology. Pre-commercial, with PDUFA set for February 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, T cell engager therapies, bispecific antibody pipeline, autoimmune disease therapeutics, oncology drug development
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Cullinan Therapeutics currently has no revenue. Future revenue will come from commercialization of approved drug products including zipalertinib (NSCLC), CLN-978 (autoimmune), velinotamig (autoimmune), and CLN-049 (AML). The company is not yet profitable and relies on equity financing and potential licensing/partnership deals.

finance.yahoo.com
2Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Partnership with Taiho Oncology/Taiho Pharmaceutical for zipalertinib development and commercialization. Taiho is responsible for completing the rolling NDA submission and will lead commercialization efforts in certain geographies, with Cullinan receiving potential milestone payments and royalties.

investors.cullinantherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engager bispecific antibodies (CLN-978, velinotamig, CLN-049) and the EGFR inhibitor zipalertinib for autoimmune diseases and cancer. Its pipeline targets high-unmet-need indications including SLE, RA, lupus nephritis, EGFR exon 20 insertion NSCLC, and AML/MDS, with commercialization led through a partnership with Taiho Oncology for its lead oncology asset.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 35% confirmed objective response rate in 176 NSCLC patients with EGFR exon 20 insertions
+5 more records
Product overview1 text field

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies in oncology and autoimmune diseases. The company's pipeline centers on T cell engager bispecific antibody programs: CLN-978 (CD19xCD3) and velinotamig (BCMAxCD3) target B cell-driven autoimmune diseases including SLE, RA, and lupus nephritis, while CLN-049 (FLT3xCD3) addresses acute myeloid leukemia. In oncology, zipalertinib (EGFR inhibitor, partnered with Taiho Oncology) is under FDA review for EGFR exon 20 insertion mutation NSCLC with PDUFA date February 27, 2027.

Product and service4 records
1CLN-978
CategoryClinical Pipeline Candidate
2Velinotamig
CategoryClinical Pipeline Candidate
3Zipalertinib
CategoryClinical Pipeline Candidate
4CLN-049
CategoryClinical Pipeline Candidate
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Cullinan Therapeutics partnered with Taiho Oncology and Taiho Pharmaceutical for the development and commercialization of zipalertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon 20 insertion mutation NSCLC. Taiho is responsible for completing the rolling NDA submission and will lead commercialization efforts in certain geographies, with Cullinan receiving potential milestone payments and royalties. The NDA is supported by Phase 2b REZILIENT1 trial data showing 35% confirmed ORR in 176 patients. PDUFA date is February 27, 2027.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Amgen is a global biopharmaceutical leader and pioneer of BiTE (bispecific T-cell engager) technology with Blincyto (CD19xCD3) approved in B-cell ALL. Directly comparable to Cullinan's TCE platform approach in both oncology and autoimmune applications, but at much larger scale.

TypeBroad incumbent
Description

Roche markets multiple T-cell engaging bispecific antibodies including mosunetuzumab (CD20xCD3) and glofitamab (CD20xCD3), and has deep autoimmune commercial infrastructure. Comparable as a broad incumbent in the bispecific T-cell engager space with overlapping oncology and autoimmune ambitions.

TypeBroad incumbent
Description

AbbVie co-developed epcoritamab (CD20xCD3, approved as Epkinly) with Genmab and has a significant autoimmune franchise. Relevant peer given bispecific TCE development and overlapping B-cell target approach for autoimmune indications like SLE and RA.

TypeBroad incumbent
Description

Regeneron is developing odronextamab (CD20xCD3) and has an established bispecific antibody platform through its Regeneron Bispecifics technology. Comparable as a TCE developer with strong oncology and autoimmune ambitions and significantly greater resources.

TypeBroad incumbent
Description

Janssen developed teclistamab (BCMAxCD3) and talquetamab (GPRC5DxCD3), and markets amivantamab (EGFRxMET) for EGFR exon 20 NSCLC directly competing with zipalertinib. Highly comparable across both Cullinan's TCE and EGFR exon 20 oncology programs.

TypeBroad incumbent
Description

AstraZeneca acquired Gracell Biotechnologies and is developing T-cell engager and cell therapy programs in autoimmune and oncology. Direct peer in TCE platform development with overlapping autoimmune ambitions and significantly greater resources.

TypeDirect peer
Description

MacroGenics is a clinical-stage biotech developing multiple DART-format bispecific T-cell engagers including flotetuzumab (CD123xCD3) and enoblituzumab. Directly comparable as a clinical-stage peer focused on bispecific antibody platforms for oncology.

TypeEmerging player
Description

Cabaletta Bio is developing CD19 CAR-T cell therapies for autoimmune diseases including SLE and lupus nephritis. Comparable as a peer pursuing deep B-cell depletion in autoimmune indications, though using cell therapy rather than bispecific TCE approach.

TypeEmerging player
Description

Kyverna Therapeutics is developing CD19 CAR-T therapies for autoimmune diseases including SLE, myositis, and MS. Emerging peer in the autoimmune B-cell depletion space with similar patient populations to Cullinan's CLN-978 and velinotamig programs.

TypeEmerging player
Description

Cartesian Therapeutics is developing engineered cell therapies and RNA-based immunotherapies for autoimmune diseases and oncology. Adjacent peer pursuing innovative immune-modulating approaches for autoimmune indications overlapping with Cullinan's TCE strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cullinan Therapeutics

Clinical-Stage Biopharmaceuticalscullinanoncology.com

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing bispecific T cell engagers (CD19xCD3, BCMAxCD3, FLT3xCD3) and the partnered EGFR inhibitor zipalertinib for autoimmune diseases and oncology. Pre-commercial, with PDUFA set for February 2027.

Cullinan Therapeutics firmographics

Firmographics
Name
Cullinan Therapeutics
Legal name
Cullinan Therapeutics, Inc.
Website
https://cullinanoncology.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing bispecific T cell engagers (CD19xCD3, BCMAxCD3, FLT3xCD3) and the partnered EGFR inhibitor zipalertinib for autoimmune diseases and oncology. Pre-commercial, with PDUFA set for February 2027.
Ownership category
akta.pro rank

Cullinan Therapeutics industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • T cell engager therapies
  • Bispecific antibody pipeline
  • Autoimmune disease therapeutics
  • Oncology drug development

Where Cullinan Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cullinan Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: As a clinical-stage biopharmaceutical company, Cullinan Therapeutics currently has no revenue. Future revenue will come from commercialization of approved drug products including zipalertinib (NSCLC), CLN-978 (autoimmune), velinotamig (autoimmune), and CLN-049 (AML). The company is not yet profitable and relies on equity financing and potential licensing/partnership deals.
  2. Licensing and Partnership Revenue: Partnership with Taiho Oncology/Taiho Pharmaceutical for zipalertinib development and commercialization. Taiho is responsible for completing the rolling NDA submission and will lead commercialization efforts in certain geographies, with Cullinan receiving potential milestone payments and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Cullinan Therapeutics product offering

Product offering

Core offering

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engager bispecific antibodies (CLN-978, velinotamig, CLN-049) and the EGFR inhibitor zipalertinib for autoimmune diseases and cancer. Its pipeline targets high-unmet-need indications including SLE, RA, lupus nephritis, EGFR exon 20 insertion NSCLC, and AML/MDS, with commercialization led through a partnership with Taiho Oncology for its lead oncology asset.

Product overview

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies in oncology and autoimmune diseases. The company's pipeline centers on T cell engager bispecific antibody programs: CLN-978 (CD19xCD3) and velinotamig (BCMAxCD3) target B cell-driven autoimmune diseases including SLE, RA, and lupus nephritis, while CLN-049 (FLT3xCD3) addresses acute myeloid leukemia. In oncology, zipalertinib (EGFR inhibitor, partnered with Taiho Oncology) is under FDA review for EGFR exon 20 insertion mutation NSCLC with PDUFA date February 27, 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • CLN-978
  • Velinotamig
  • Zipalertinib
  • CLN-049

Quantifiable outcome

  • 35% confirmed objective response rate in 176 NSCLC patients with EGFR exon 20 insertions
  • +5 more outcomes

Companies that use Cullinan Therapeutics

Customer profile

Segments3 records

Ideal customer profiles1 record

Cullinan Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cullinan Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Taiho Oncology / Taiho PharmaceuticalcoreStrategic or Co-development Partner · 1 November 2025Cullinan Therapeutics partnered with Taiho Oncology and Taiho Pharmaceutical for the development and commercialization of zipalertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon 20 insertion mutation NSCLC. Taiho is responsible for completing the rolling NDA submission and will lead commercialization efforts in certain geographies, with Cullinan receiving potential milestone payments and royalties. The NDA is supported by Phase 2b REZILIENT1 trial data showing 35% confirmed ORR in 176 patients. PDUFA date is February 27, 2027.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Cullinan Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Amgen: Amgen is a global biopharmaceutical leader and pioneer of BiTE (bispecific T-cell engager) technology with Blincyto (CD19xCD3) approved in B-cell ALL. Directly comparable to Cullinan's TCE platform approach in both oncology and autoimmune applications, but at much larger scale.
  • Roche: Roche markets multiple T-cell engaging bispecific antibodies including mosunetuzumab (CD20xCD3) and glofitamab (CD20xCD3), and has deep autoimmune commercial infrastructure. Comparable as a broad incumbent in the bispecific T-cell engager space with overlapping oncology and autoimmune ambitions.
  • AbbVie: AbbVie co-developed epcoritamab (CD20xCD3, approved as Epkinly) with Genmab and has a significant autoimmune franchise. Relevant peer given bispecific TCE development and overlapping B-cell target approach for autoimmune indications like SLE and RA.
  • Regeneron Pharmaceuticals: Regeneron is developing odronextamab (CD20xCD3) and has an established bispecific antibody platform through its Regeneron Bispecifics technology. Comparable as a TCE developer with strong oncology and autoimmune ambitions and significantly greater resources.
  • Johnson & Johnson (Janssen): Janssen developed teclistamab (BCMAxCD3) and talquetamab (GPRC5DxCD3), and markets amivantamab (EGFRxMET) for EGFR exon 20 NSCLC directly competing with zipalertinib. Highly comparable across both Cullinan's TCE and EGFR exon 20 oncology programs.
  • AstraZeneca: AstraZeneca acquired Gracell Biotechnologies and is developing T-cell engager and cell therapy programs in autoimmune and oncology. Direct peer in TCE platform development with overlapping autoimmune ambitions and significantly greater resources.

Direct peers

  • MacroGenics: MacroGenics is a clinical-stage biotech developing multiple DART-format bispecific T-cell engagers including flotetuzumab (CD123xCD3) and enoblituzumab. Directly comparable as a clinical-stage peer focused on bispecific antibody platforms for oncology.

Emerging players

  • Cabaletta Bio: Cabaletta Bio is developing CD19 CAR-T cell therapies for autoimmune diseases including SLE and lupus nephritis. Comparable as a peer pursuing deep B-cell depletion in autoimmune indications, though using cell therapy rather than bispecific TCE approach.
  • Kyverna Therapeutics: Kyverna Therapeutics is developing CD19 CAR-T therapies for autoimmune diseases including SLE, myositis, and MS. Emerging peer in the autoimmune B-cell depletion space with similar patient populations to Cullinan's CLN-978 and velinotamig programs.
  • Cartesian Therapeutics: Cartesian Therapeutics is developing engineered cell therapies and RNA-based immunotherapies for autoimmune diseases and oncology. Adjacent peer pursuing innovative immune-modulating approaches for autoimmune indications overlapping with Cullinan's TCE strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Cullinan Therapeutics social profiles

Digital presence

Cullinan Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cullinan Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Cullinan Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cullinan Therapeutics M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cullinan Therapeutics

What does Cullinan Therapeutics do?

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engager bispecific antibodies (CLN-978, velinotamig, CLN-049) and the EGFR inhibitor zipalertinib for autoimmune diseases and cancer. Its pipeline targets high-unmet-need indications including SLE, RA, lupus nephritis, EGFR exon 20 insertion NSCLC, and AML/MDS, with commercialization led through a partnership with Taiho Oncology for its lead oncology asset.

Is Cullinan Therapeutics a public or private company?

Cullinan Therapeutics is a public company. It is classified as public and is currently operating.

When was Cullinan Therapeutics founded?

Cullinan Therapeutics was founded in 2016. It employs 101 to 250 people.

Where is Cullinan Therapeutics based?

Cullinan Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Cullinan Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.

Who are Cullinan Therapeutics's main competitors?

Broad incumbents on record are Amgen, Roche, AbbVie, Regeneron Pharmaceuticals, Johnson & Johnson (Janssen) and AstraZeneca. MacroGenics is listed as a direct peer. Emerging players are Cabaletta Bio, Kyverna Therapeutics and Cartesian Therapeutics.

Does Cullinan Therapeutics have an API?

No public API is recorded for Cullinan Therapeutics.

What industry is Cullinan Therapeutics in?

Cullinan Therapeutics's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaCullinan Therapeutics, Inc. (CGEM) Presents at UBS Global Biopharma Conference 2026 TranscriptCullinan Therapeutics presented at the UBS Global Biopharma Conference, with CEO Nadim Ahmed and CMO Jeff Jones discussing its T-cell engager pipeline. The company highlighted three programs: CD19 and BCMA T-cell engagers for autoimmune disease, and an FLT3 T-cell engager for AML, with multiple milestones expected in coming weeks.American Banking and Market NewsCullinan Therapeutics, Inc. $CGEM Shares Bought by Fisher Asset Management LLCFisher Asset Management increased its stake in Cullinan Therapeutics by 2,125% in Q3, buying 764,963 shares to hold 800,961 shares (1.24% of the company). Insider Jennifer Michaelson sold 8,000 shares on September 8th. Analysts have a consensus 'Moderate Buy' rating with a price target of $34.14.TradingViewCullinan Therapeutics, Inc. Stock 12‑Month Price Target Raised to $35.6, Implies 246% UpsideAnalysts' average price target for Cullinan Therapeutics rose to $35.6 from $34.75, implying about 246% upside from the Nov. 13 close. The consensus remains a Buy across 11 analysts, with forecasts ranging from $23 to $47 per share.Seeking AlphaCullinan Therapeutics reports Q3 results (NASDAQ:CGEM)Cullinan Therapeutics reported a Q3 net loss of $49.4 million, down from $50.6 million in the same period of 2025. As of September 30, 2026, the company held $313.8 million in cash and investments, with management expecting runway into 2029 under its current operating plan.The future of tradingCullinan Therapeutics Q3 net loss narrows to $49.4 millionCullinan Therapeutics reported a Q3 2026 net loss of $49.4 million, down from the prior year. Cash and investments stood at $313.8 million, with operations funded into 2029. Taiho initiated zipalertinib's first-line combination therapy NDA submission, with completion expected in November.The future of tradingCullinan Therapeutics Reports Anti-Leukemic Activity in Phase 1 CLN-049 StudyCullinan Therapeutics will present CLN-049 and velinotamig research at the ASH annual meeting in New Orleans, December 12-15, 2026. A Phase 1 abstract reports anti-leukemic activity with a favorable safety profile in relapsed or refractory leukemia or myelodysplastic syndrome. Updated results for CLN-049 regimens selected for Phase 2 will be presented December 13.YahooLearn Why The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following Trial ClearanceCullinan Therapeutics reported FDA and TGA clearance of a global Phase 1b/2a trial of velinotamig for autoimmune cytopenias. The company's investment narrative now includes this autoimmune angle alongside its T cell engager pipeline, though it does not replace the need for late-stage assets. Progress on zipalertinib remains the key swing factor for revenue forecasts.YahooCullinan Therapeutics (CGEM) Wins Trial Clearance, Is The Upside Already Priced In?Cullinan Therapeutics received regulatory clearance for a global Phase 1b/2a trial of velinotamig in immune thrombocytopenia and warm autoimmune hemolytic anemia. The stock has returned 48.52% year-to-date, but the share price trades below the implied fair value of $33.55, suggesting potential undervaluation. Early clinical responses in severe SLE support further development in autoimmune disease.American Banking and Market NewsCullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, BTIG Research Analyst SaysBTIG Research raised its Cullinan Therapeutics target price to $41 from $40, keeping a buy rating. The stock opened at $15.45, with a consensus price target of $33.86 and an average rating of Moderate Buy. Insider Jennifer Michaelson sold 30,000 shares at $20.26.MarketBeatCullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on ThursdayCullinan Therapeutics is expected to report Q3 2026 earnings on Thursday, with analysts projecting a loss of $0.84 per share and revenue of $2.00 million. The company's stock opened at $15.56, and analysts have an average rating of Moderate Buy with a price target of $33.86.